REGENXBIO Investors Urged to Join Securities Fraud Lawsuit

The Schall Law Firm reminds investors of a class action lawsuit against REGENXBIO Inc. for violations of securities laws.

Published on Feb. 17, 2026

Got story updates? Submit your updates here. ›

The Schall Law Firm, a national shareholder rights litigation firm, has reminded investors of a class action lawsuit against REGENXBIO Inc. ('Regenxbio') for violations of securities laws. The lawsuit covers the period from February 9, 2022 to January 27, 2026, during which the company allegedly made false and misleading statements to investors about the efficacy and safety of its product candidate RGX-111.

Why it matters

This lawsuit highlights the importance of transparency and accurate disclosures by public companies, as investors rely on this information to make informed decisions. The alleged concealment of negative data on RGX-111 could have significant implications for the company and its shareholders.

The details

According to the complaint, Regenxbio made overwhelmingly positive statements to investors about RGX-111, while concealing negative data on its efficacy and safety. The company later revealed that an intraventricular CNS tumor was discovered in a participant treated as part of an RGX-111 study, indicating that the company's previous public statements were false and materially misleading.

  • The class period covers the period from February 9, 2022 to January 27, 2026.
  • Investors have until April 14, 2026 to contact the Schall Law Firm to participate in the lawsuit.

The players

REGENXBIO Inc.

A biotechnology company focused on the development of gene therapy products.

The Schall Law Firm

A national shareholder rights litigation firm that specializes in securities class action lawsuits and shareholder rights litigation.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.”

— Brian Schall, Attorney, Schall Law Firm (Business Wire)

What’s next

The judge in the case will decide on April 14, 2026 whether to certify the class action lawsuit.

The takeaway

This lawsuit highlights the importance of transparency and accurate disclosures by public companies, as investors rely on this information to make informed decisions. The alleged concealment of negative data on RGX-111 could have significant implications for REGENXBIO and its shareholders.